Medication info
Candelova Tablets 10/8 mg

Candelova Tablets 10/8 mg

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›10.4mg / 1 tabletCandesartan Cilexetil›8mg / 1 tablet
Manufacturer / importer
Kyungbo Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets (10 tablets/PTP x 3) - 30 tablets/PTP[30 tablets (10 tablets/PTP x 3)]
Approval status
Active

MFDS item code 202008714 · Approved 2020.12.11

Summary

Main use
Improvement of dyslipidemia; treatment of hypertension and heart failure; suppression of atherosclerosis and cardiovascular risk
Who takes it
Adults · Children
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: Administer an initial dose of 4 mg with careful caution in patients at increased risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those receiving hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure 1) Adults: The recommended initial dose is 4 mg once daily. The dose may be doubled at intervals of 2 weeks or more, up to a maximum of 32 mg once daily, depending on the patient's tolerability. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and should continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or more according to the LDL cholesterol level, treatment goal, and patient response, and may be increased to a maximum of 20 mg per day. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience in patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.
Child dose
○ Candesartan cilexetil 1. Essential hypertension 6) Children: The safety and efficacy of this medicine have not been established in adolescents and children 18 years of age or younger. 2. Heart failure 3) Children: The safety and efficacy of this medicine have not been established in adolescents and children 18 years of age or younger.

Ingredients

Manufacturer
Kyungbo Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of dyslipidemia; treatment of hypertension and heart failure; suppression of atherosclerosis and cardiovascular risk

  • Essential hypertension
  • impaired left ventricular systolic function
  • poor tolerance to ACE inhibitors
  • primary hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • abnormal beta-lipoproteinemia
  • hypercholesterolemia
  • risk of stroke
  • risk of myocardial infarction
  • risk of revascularization procedures
View approved original text

This medication is used for patients who need simultaneous administration of two components, namely Candesartan Cilexetil and Rosuvastatin. Candesartan Cilexetil is indicated for patients with essential hypertension and heart failure with impaired left ventricular function, particularly those requiring additional treatment to ACE inhibitors or those who are intolerant. Rosuvastatin helps in managing hyperlipidemia and mixed dyslipidemia, and delaying the progression of atherosclerosis, and is used to reduce the risk of stroke, myocardial infarction, and revascularization procedures in high-risk cardiovascular patients. By combining the two components, hypertension and hyperlipidemia can be effectively managed. Dosage should be individualized based on the patient's condition and tolerance, and this medication is primarily recommended for adult patients. It is used to control blood pressure and cholesterol levels simultaneously to improve cardiovascular health.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: Administer an initial dose of 4 mg with careful caution in patients at increased risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those receiving hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure 1) Adults: The recommended initial dose is 4 mg once daily. The dose may be doubled at intervals of 2 weeks or more, up to a maximum of 32 mg once daily, depending on the patient's tolerability. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and should continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or more according to the LDL cholesterol level, treatment goal, and patient response, and may be increased to a maximum of 20 mg per day. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience in patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.

Child dose

○ Candesartan cilexetil 1. Essential hypertension 6) Children: The safety and efficacy of this medicine have not been established in adolescents and children 18 years of age or younger. 2. Heart failure 3) Children: The safety and efficacy of this medicine have not been established in adolescents and children 18 years of age or younger.

Precautions

This medication can cause severe harm to the fetus if taken during pregnancy, particularly in the second and third trimesters, so it should be discontinued immediately if pregnancy is confirmed. Women who may become pregnant should use appropriate contraception before taking this medication, and it is advisable to avoid this medication while breastfeeding. This medication should not be given to patients with certain liver diseases or severe kidney disorders, and those with congenital lactose intolerance should also avoid it. Elderly patients, patients with impaired liver function, and patients with high serum potassium levels should use this medication with particular caution and undergo regular liver and kidney function tests. If muscle pain or weakness, or sudden muscle pain occurs, consult a doctor immediately, and if these symptoms are severe or muscle enzyme levels rise, discontinuation of medication may be necessary. This medication may interact with other drugs, so inform your doctor or pharmacist if you are taking any other medications, especially when taken with diuretics, potassium-sparing agents, certain antibiotics, antifungals, etc. In case of overdose, symptoms such as hypotension, dizziness, and tachycardia may occur, necessitating an immediate hospital visit for appropriate treatment. There may be dizziness or fatigue when driving or operating machinery, so caution is advised. Keep this medication out of the reach of children, and it is safe not to transfer the medication to another container.

Side effects

headache, nasopharyngitis, localized infection, fatigue, generalized pruritus, dermatitis, itching, joint stiffness, limb pain, photophobia, dyspepsia, elevated blood sugar, decreased serum sodium, hand fractures, hypoglycemia, nephrolithiasis, cough, urticaria, nausea, dizziness, position-dependent dizziness, milia, periodontitis, chest discomfort, inflammation, musculoskeletal pain, neck pain, cataract, thrombocytopenia, jaundice, hepatitis, rash, angioedema, myalgia, fatigue, increased creatine kinase, elevated myoglobin in blood and urine, rhabdomyolysis, arthralgia, low back pain, renal impairment, acute renal failure, interstitial pneumonia, shock, syncope, loss of consciousness, paralysis, hypertonia, facial flushing, weight gain, facial edema, thirst, sleep disorders, decreased libido, forgetfulness, loss of appetite, increased appetite, tinnitus, altered taste, erectile dysfunction, angioedema, constipation, abdominal pain, pancreatitis, rash and urticaria, myopathy, immune-mediated necrotizing myopathy, lupus-like syndrome, muscle rupture, amnesia, peripheral neuropathy, dyspnea, diarrhea, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, hematuria, edema, depression, sleep disorders, liver failure, cognitive impairment, severe muscle weakness, ocular myasthenia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly sealed container to prevent exposure to air or moisture. Additionally, it should be stored at room temperature between 1°C and 30°C, avoiding extremely cold or hot places.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets (10 tablets/PTP x 3) - 30 tablets/PTP[30 tablets (10 tablets/PTP x 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.